Immuno-Oncology Assays
Immuno-Oncology Platform

Immuno-Oncology Assays

The immuno-oncology assay suite from Reaction Biology enables researchers to understand how a new drug candidate modulates the immune response against tumor cells. Our immune cell-based assays are comprised of killing assays that elucidate the potency of immunotherapies, either via bringing the cytotoxic immune cells into the proximity of tumor target cells or via promoting tumor cell killing via T cell activation or overcoming tolerance.

Immune cells have distinctive ways of recognizing malignant cells as targets and thus we have developed immune cell-based killing assays utilizing T cells and NK cells. We are also in the process of developing monocyte-based killing assays.

Our immune cell assay services characterize immune cells by their proliferation, polarization, or activation status. Many of these services can be custom-tailored to the specific needs of each research project.

Reach out today to discuss your immuno-oncology research needs with our scientists.

Immuno-Oncology Assays

Immunotherapies help the immune system to fight cancer. This is achieved by various strategies which can be investigated by immune cell assays, including:

  • activating immune cells
  • triggering immune cell proliferation
  • overcoming exhaustion of immune cells
  • helping immune cells infiltrate the tumor
  • recognizing a target tumor cell
  • triggering tumor cell killing

Tumor Killing assays

Cytotoxic immune cells such as CD8+ T cells or NK cells can recognize and kill cancer cells. Our killing assays enable testing of drugs that enhance or facilitate tumor cell killing by T cells, NK cells, or, soon, monocytes.


Immune Cell Assays

Our suite of assays for immune cell characterization enables researchers to quantify the immune-modulatory action of their drug candidates by investigating the immune cell’s activation status, markers, and proliferation.


Ex Vivo Immunophenotyping 

New immunotherapeutic drug candidates can be tested in our animal testing unit on cell line-derived or tissue-derived mouse tumor models. To understand their immune-modulatory potency, we offer various immunophenotyping options, including flow cytometry, histology, and multiplex protein quantification assays.